Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Nanus

Showing results (101-110 of 168) with videos related to

Pageof 17
Sort By:
Frontiers in Oncology|March 8, 2021
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate CancerPanagiotis J Vlachostergios, Muhammad Junaid Niaz, Michael Sun, et al.
The Prostate|January 19, 2021
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancerPanagiotis J Vlachostergios, Muhammad Junaid Niaz, Myrto Skafida, et al.
Cancer Biology & Therapy|February 1, 2023
NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinomaJaclyn M Kubala, Kristian B Laursen, Ryan Schreiner, et al.
Cancer|April 24, 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancerScott T Tagawa, Shankar Vallabhajosula, Paul J Christos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate CancerSantosh Gupta, Susan Halabi, Qian Yang, et al.
Prostate Cancer and Prostatic Diseases|April 1, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)Santosh Gupta, Siyuan Guo, Susan Halabi, et al.
Urologic Oncology|October 22, 2016
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancerMatthew I Milowsky, Matthew D Galsky, Michael J Morris, et al.
The Oncologist|January 31, 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (<sup>177</sup> Lu-J591) for Metastatic Castration-Resistant Prostate CancerMuhammad Junaid Niaz, Jaspreet S Batra, Ryan D Walsh, et al.
Neoplasia (New York, N.Y.)|January 30, 2013
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancerJuan Miguel Mosquera, Himisha Beltran, Kyung Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Pageof 17

Showing results (101-110 of 168) with videos related to

Sort By:
Pageof 17
Frontiers in Oncology|March 8, 2021
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate CancerPanagiotis J Vlachostergios, Muhammad Junaid Niaz, Michael Sun, et al.
The Prostate|January 19, 2021
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancerPanagiotis J Vlachostergios, Muhammad Junaid Niaz, Myrto Skafida, et al.
Cancer Biology & Therapy|February 1, 2023
NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinomaJaclyn M Kubala, Kristian B Laursen, Ryan Schreiner, et al.
Cancer|April 24, 2019
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (<sup>177</sup> Lu-J591) for metastatic castration-resistant prostate cancerScott T Tagawa, Shankar Vallabhajosula, Paul J Christos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2023
PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate CancerSantosh Gupta, Susan Halabi, Qian Yang, et al.
Prostate Cancer and Prostatic Diseases|April 1, 2026
Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial)Santosh Gupta, Siyuan Guo, Susan Halabi, et al.
Urologic Oncology|October 22, 2016
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancerMatthew I Milowsky, Matthew D Galsky, Michael J Morris, et al.
The Oncologist|January 31, 2020
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (<sup>177</sup> Lu-J591) for Metastatic Castration-Resistant Prostate CancerMuhammad Junaid Niaz, Jaspreet S Batra, Ryan D Walsh, et al.
Neoplasia (New York, N.Y.)|January 30, 2013
Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancerJuan Miguel Mosquera, Himisha Beltran, Kyung Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.
Pageof 17